Document is current
Any future updates will be listed below
-
Authors
Derraz, Bouchra
Breda, Gabriele
Kaempf, Christoph https://orcid.org/0000-0002-3470-6779
Baenke, Franziska https://orcid.org/0000-0001-9389-4688
Cotte, Fabienne
Reiche, Kristin https://orcid.org/0000-0002-4452-4872
Köhl, Ulrike https://orcid.org/0000-0002-8159-9160
Kather, Jakob Nikolas
Eskenazy, Deborah
Gilbert, Stephen https://orcid.org/0000-0002-1997-1689
-
Funding
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (16KISA100K)
- License Information
-
More Information
Article History
Received: 18 August 2023
Accepted: 6 January 2024
First Online: 30 January 2024
Competing interests
: B.D., G.B., F.B., K.R., C.K., D.E. declare no Competing Financial or Non-Financial Interests. Authors declare the following Non-Financial Interests: S.G.: Advisory Group member of the EY-coordinated ‘Study on Regulatory Governance and Innovation in the field of Medical Devices’ conducted on behalf of the DG SANTE of the European Commission. Authors declare the following Competing Financial Interests: Author S.G. has or has had consulting relationships with Una Health GmbH, Lindus Health Ltd.; Flo Ltd, Thymia Ltd., FORUM Institut für Management GmbH, High-Tech Gründerfonds Management GmbH, Ada Health GmbH, and he holds share options in Ada Health GmbH. Author J.N.K.: consulting services for Owkin, France; DoMore Diagnostics, Norway and Panakeia, UK, he holds shares in StratifAI GmbH and he has received honoraria for lectures by Bayer, Eisai, MSD, BMS, Roche, Pfizer, and Fresenius. Author U.K.: Has consulted for and/or has received speaker fees from AstraZeneca, Affimed, Glycostem, GammaDelta, Zelluna, Miltenyi Biotec and Novartis Pharma GmbH, Bristol-Myers Squibb GmbH & Co. KGaA. F.C.: employee of Ada Health GmbH. Furthermore, J.N.K. is a Deputy Editor at npj Precision Oncology. J.N.K. played no role in the internal review or decision to publish this article.
